Cytokinetics

$50.30 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Cytokinetics

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Stock Analysis

last close $50.3
1-mo return 12.8%
3-mo return 31.2%
avg daily vol. 1.53M
52-week high 54.74
52-week low 29.1
market cap. $4.9B
forward pe -
annual div. -
roe -338%
ltg forecast -
dividend yield -
annual rev. $151M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe